PHC Holdings Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PHC Holdings Corporation
Ripples from the COVID-19 pandemic can be felt across Asia Pacific as investment from foreign firms into the region dropped by 45% from 2019 to 2020, and continued its decline in 2021 to 34%.
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
Sanofi and Regeneron teamed up in a second major deal, focused on immuno-oncology; after an unsuccessful try at Mylan, Teva bought Allergan's generics business. Between June and July, biopharma companies raised over $10 billion, and device firms more than $1 billion.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.
- In Vitro Diagnostics
- Medical Devices
- Managed Care, Insurance, Integrated Systems
- Outcomes Studies
- Services sold to health care facilities
- Specialized outpatient services
- Utilization Review, Claims Processing, Cost Contai
Managed Care, Insurance, Integrated Systems
- Specialized Provider Networks
- Other Names / Subsidiaries
- Ascensia Diabetes Care Holdings
- Panasonic Healthcare Holdings Co., Ltd
- Panasonic Healthcare Co., Ltd.